Spark Therapeutics issued a press release on updated preliminary data from 10 infused participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for hemophilia B. The data is聽being presented at Hemostastis &聽Thrombosis Research Society (HTRS) this week.

The press release can be read in full here.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.